Ionis Pharmaceuticals (IONS) Tops Q4 EPS by $1.13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts IONS Hot Sheet
Join SI Premium – FREE
Ionis Pharmaceuticals (NASDAQ: IONS) reported Q4 EPS of $1.41, $1.13 better than the analyst estimate of $0.28. Revenue for the quarter came in at $440 million versus the consensus estimate of $259.15 million.
For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can broadening earnings growth sustain the equity upcycle? JPM weighs in
- UBS Reiterates Neutral Rating on Tractor Supply Company (TSCO) Amid Focus on Top-Line Trends
- Interactive Brokers among ‘best-positioned brokerage platforms’ says Deutsche Bank
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
